Moderna (MRNA) closed at $34.01 in the latest trading session, marking a -1.9% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

Overall, the performance of MRNA stock with respect to the index has been quite volatile. Returns for the stock were 143% in 2021, -29% in 2022, and -45% in 2023.

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Moderna's Q1 2022 financial performance was better than expected, but MRNA didn't raise full-year 2022 guidance. See if MRNA stock is a buy, sell, or hold.

Moderna's performance slowed as the pandemic's worst effects began to wane. The company is notching important clinical and regulatory wins. The vaccine maker has a deep pipeline and the funds to ...

Moderna updated FY21 revenue guidance that came in below consensus estimates. The company also faces logistical issues. Find out if MRNA stock is a buy.

Moderna stock (NASDAQ: MRNA) has rallied from around $104 per share at the end of 2020, to about $485 as of Monday, an increase of over 4.5x. This compares to the S&P 500 which is up by just about ...

Moderna stock declined by about 30% over the last week (five trading days) following the company’s weaker than expected Q3 2021 results. While Moderna’s revenue for Q3 grew by almost 13% ...